Medtronic Inc (MDT: Quote) Friday announced positive results from the trial of its Simplicity Renal Denervation System.
The company stated that the six month pooled outcomes from randomized and crossover patients in the Simplicity HTN-2 clinical trial following renal denervation with the Simplicity renal denervation system showed significant and sustained reduction in blood pressure among those patients suffering with treatment-resistant hypertension.
Medtronic further noted that the pooled analysis included change in blood pressure at six months for all patients randomized to receive renal denervation with Symplicity at baseline (n=49), as well as patients in the control group (n=35) who met entry criteria and crossed over to the treatment group following assessment of the initial six month primary endpoint.
Renal denervation therapy is a minimally invasive, catheter-based procedure that modulates the output of nerves that lie within the renal artery wall and lead into and out of the kidneys. These nerves are part of the sympathetic nervous system, which affects the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidneys and the blood vessels.
Click here to receive FREE breaking news email alerts for Medtronic Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org